S-omeprazole magnesium

Details S-omeprazole magnesium S-omeprazole magnesium

2011-01-25

2011-01-25

Morris, Patricia L (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07875723

ABSTRACT:
The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1% by weight as determined by high performance liquid chromatography (HPLC).

REFERENCES:
patent: 6369085 (2002-04-01), Cotton et al.
patent: 6713495 (2004-03-01), Sherman
patent: 6894066 (2005-05-01), Sherman
patent: 7169793 (2007-01-01), Reddy et al.
patent: 2003/0212274 (2003-11-01), Vijayaraghavan et al.
patent: 2004/0235903 (2004-11-01), Khanna et al.
patent: WO9207816 (1992-05-01), None
patent: WO9427988 (1994-12-01), None
patent: WO9501977 (1995-01-01), None
patent: WO9602535 (1996-02-01), None
patent: WO9702261 (1997-01-01), None
patent: WO9741114 (1997-11-01), None
patent: WO03051867 (2003-06-01), None
patent: WO03089408 (2003-10-01), None
patent: WO2004046134 (2004-06-01), None
patent: WO2006069159 (2006-06-01), None
Brittain ed., Polymorphism in Pharmaceutical Sciences, NY: Marcel Dekker, 1999, pp. 1-2, 185-226.
Caira, “Crystalline Polymorphism of Organic Compounds,” Topics in Current Chemistry, 198, Springer Verlag Berlin Heidelberg, 1998, 163-208.
Chopra et al., “Formulation and the Solid State of Drugs,” Pharmacos, 25 (1981), pp. 39-45.
Doelker, “Physicochemical Behaviors of Active Substances Their Consequences for the Feasibility and the Stability of Pharmaceutical Forms,” English translation of S.T.P. Pharma Pratiques (1999), 9(5), 2999-409, pp. 1-33.
Hawley's Condensed Chemical Dictionary, 13th Ed., NY: John Wiley & Sons, Inc., 1997, 68.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6), 315-329.
Muzaffar et al., “Polymorphism and Drug Availability,”J of Pharmacy (Lahore), 1979, 1(1), 59-66.
Nerurkar et al., “Properties of Solids That Affect Transport,” Transport Processes in Pharmaceutical Systems, NY Marcel Dekker, Inc., 2000, 575-611.
Singhal et al., Drug Polymorphism and Dosage Form Design: a Practical Perspective, Advanced Drug Delivery Reviews 56 (2004) 335-347.
Threifall, “Analysis of Organic Polymorphs A Review” Analyst, 1995, 120, 2435-2460.
Ulicky et al., “Comprehensive Dictionary of Physical Chemistry,” NY: Prentice Hall, 1992, 21.
Xu, “Dynamic Vapor Sorportion,” J Of Zhejiang University of Technology, 31(4), 2003, 456-459; an English Translation of the Abstract.
Xu, “Dynamic Vapor Sorportion,” J Of Zhejiang University of Technology, 31(4), 2003, 456-459.

Affiliated with

Also associated with

Rating

S-omeprazole magnesium does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with S-omeprazole magnesium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S-omeprazole magnesium will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2621165